鼻喷激素与白三烯受体拮抗剂治疗儿童腺样体肥大临床观察比较

发布时间：2018-09-13 13:57

【摘要】：目的:探讨并比较儿童腺样体肥大患者使用鼻喷激素或白三烯受体拮抗剂治疗的临床效果。方法:对我院2011年6月至2013年8月收治的160例腺样体肥大患儿,随机分为治疗组和对照组,治疗组分为鼻喷激素治疗组(雷诺考特)、白三烯受体拮抗剂治疗组(孟鲁司特钠)以及雷诺考特与孟鲁司特钠联用治疗组,每组患儿各40例,并观察临床症状指标评分及腺样体厚度/鼻咽腔宽度(Adenoido/Nasopharyngeal比值)的改变。结果:鼻喷激素治疗组患儿临床症状综合评分较对照组明显下降,分别为3.20±0.29、3.27±0.48及3.50±0.17,差异具有统计学意义(2组比较均P=0.000),腺样体厚度/鼻咽腔宽度比降至0.60以下;白三烯受体拮抗剂治疗组患儿临床症状综合评分较对照组明显下降,分别为3.49±0.45、3.61±0.32及3.41±0.39,差异具有统计学意义(两组比较均P=0.000),腺样体厚度/鼻咽腔宽度比降至0.71以下;联合治疗组患儿临床症状综合评分较对照组明显下降,分别为3.02±0.13、3.22±0.41及3.38±0.12,差异具有统计学意义(两组比较均P=0.000),腺样体厚度/鼻咽腔宽度比降至0.60以下;联合治疗组部分临床症状评分优于单独给药组(2组比较均P=0.000);联合治疗组改善腺样体体积疗效优于单独给药组(P分别为0.05、0.001及0.001)。结论:鼻喷激素(雷诺考特)与白三烯受体拮抗剂(孟鲁司特钠)能有效改善儿童腺样体肥大患者的临床症状,且联合治疗组疗效优于单独给药组。
[Abstract]:Objective: to investigate and compare the clinical effects of nasal spray hormone or leukotriene receptor antagonist in children with adenoid hypertrophy. Methods: from June 2011 to August 2013, 160 children with adenoid hypertrophy were randomly divided into treatment group and control group. The treatment group was divided into three groups: the nasal spray hormone treatment group (Renolcott), the leukotriene receptor antagonist treatment group (montelukast sodium) and the combined treatment group with Renolcotte and montelukast sodium, with 40 children in each group. The clinical symptom score and the ratio of adenoid thickness to nasopharyngeal cavity width (Adenoido/Nasopharyngeal) were observed. Results: compared with the control group, the scores of clinical symptoms in the treatment group were significantly lower than those in the control group (3.20 卤0.29 卤3.27 卤0.48 and 3.50 卤0.17, respectively). The difference was statistically significant (P < 0.000), and the ratio of adenoid thickness to the width of nasopharynx was less than 0.60. The comprehensive scores of clinical symptoms in the leukotriene receptor antagonist group were significantly lower than those in the control group, which were 3.49 卤0.45v 3.61 卤0.32 and 3.41 卤0.39, respectively. The difference was statistically significant (P < 0.000), and the ratio of adenoid thickness to nasopharyngeal cavity width decreased to less than 0.71. The scores of clinical symptoms in the combined treatment group were significantly lower than those in the control group (3.02 卤0.13 卤3.22 卤0.41 and 3.38 卤0.12, respectively), the difference was statistically significant (P < 0.000), and the ratio of adenoid thickness to nasopharyngeal cavity width was lower than 0.60; The clinical symptom score of the combined treatment group was better than that of the single administration group (P0. 000), and the effect of the combined treatment group on improving the volume of adenoids was better than that of the single administration group (P = 0. 05 0. 001 and 0.001, respectively). Conclusion: nasal spray hormone (Renault) and leukotriene receptor antagonist (montelukast sodium) can effectively improve the clinical symptoms of children with adenoid hypertrophy, and the curative effect of the combined treatment group is better than that of the single administration group.
【作者单位】：重庆医科大学附属儿童医院耳鼻咽喉科;
【基金】：重庆市卫生局课题资助项目(编号:20142042)
【分类号】：R766

【参考文献】